Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

Prey, S.; Paul, C.; Bronsard, V.; Puzenat, E.; Gourraud, Pierre-Antoine; Aractingi, S.; Aubin, F.; Bagot, Martine; Cribier, B.; Joly, P.; Jullien, D.; Maître, Michel; Richard-Lallemand, M.-A.; Ortonne, Jean‐Paul

doi:10.1111/j.1468-3083.2009.03565.x

Cited by 131 publications

(103 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is, therefore, unsurprising that patients with IMIDs frequently suffer from related conditions. Psoriatic arthritis (PsA) -an erosive, polyarticular, joint damaging disease that can progress to the loss of function -occurs in 10-34% of individuals with psoriasis, compared with a rate of 0.04-1.2% in unaffected individuals (13,73,74). Prevalence of psoriasis has been shown to be significantly higher in patients with inflammatory bowel disease (CD or ulcerative colitis), compared with controls.…”

Section: The Relationship Between Psoriasis and Other Imidsmentioning

confidence: 99%

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Girolomoni

Griffiths

Krueger

et al. 2014

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact on a patient's life, especially when the disease is moderate to severe. There is evidence that treatment of psoriasis during the first years is conservative and frequently based on topical agents which rarely clear lesions. Treatment with systemic agents including biologics is often undertaken only when topical agents have proved unsuitable, even in patients with moderate to severe disease. However, there is evidence that in other IMIDs (rheumatoid arthritis and Crohn's disease), targeted systemic treatment given early in the treatment pathway may improve long-term patient outcomes. We hypothesize that a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway (''early intervention'') with the goal of complete clearance, may improve control of cutaneous symptoms and may also modify disease course and burden. Critical points to address when designing an early intervention study would include: the definition of psoriasis disease activity; patient selection; intervention selection; and dosing strategies.

show abstract

Section: The Relationship Between Psoriasis and Other Imidsmentioning

confidence: 99%

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Girolomoni

Griffiths

Krueger

et al. 2014

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Причиной низкой заболеваемости ПсА мо-жет быть его недостаточная диагностика, особенно на ранней стадии [15]. Важную роль в проведении регист-рации играют врачи дерматовенерологи, с которыми па-циенты сталкиваются в первую очередь, так как в боль-шинстве (70%) случаев псориаз предшествует артриту [16,17]. С другой стороны, с учетом отсутствия паралле-лизма между кожным и суставным процессами, необхо-димо взаимодействие двух специалистов -дерматовене-ролога и ревматолога, поскольку в результате сложив-шейся клинической практики пациенты с преимущест-венным поражением кожи обращаются на консультацию к дерматологу, а с суставными жалобами -к ревматоло-гу.…”

Section: Discussionunclassified

“…В одном из первых исследований по выявлению ПсА у больных псориазом, проведенном недавно в Российской Федера-ции на базе дерматологической и ревматологической кли-ник, было показано, что избыточная диагностика ПсА дер-матологами составила 30%. В большинстве случаев при псориазе развивается ПсА, однако у части пациентов рев-матическое заболевание не найдено, несмотря на наличие суставных жалоб, а у меньшего числа выявлено другое рев-матическое заболевание (ревматоидный артрит, реактив-ный артрит, анкилозирующий спондилит, ревматическая полимиалгия) [17].…”

Section: Discussionunclassified

“…Другие исследования показали, что почти у 1/3 больных псориазом дерматолог не заподозрил ПсА, хотя в дальнейшем при обследовании этот диагноз был уста-новлен ревматологом [13,15,17]. Несомненно, это свя-зано с высокой клинической гетерогенностью ПсА, при котором часто наблюдается не только артрит, но и спондилит или энтезит.…”

Section: Discussionunclassified

See 1 more Smart Citation

Incidence of Psoriatic Arthritis in Russia: Trends at the Present Stage and Prospects

Мишина¹,

Korotaeva²,

Стародубов³

et al. 2015

rsp

View full text Add to dashboard Cite

“…[1][2][3] The high variability in study setting, data quality regarding cardiovascular risk factors assessment and choice of control group was acknowledged. As comorbid conditions may impact therapeutic approach in psoriasis, the objective of this study was to elaborate practical recommendations to help practitioners to better appraise the risk of cardiovascular events, cancer and alcohol abuse in psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence‐based recommendations based on systematic review and expert opinion

Richard

Barnetche²,

Horreau

et al. 2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

The relationship between psoriasis, chronic inflammation, cardiovascular risk and risk of cancer has long been debated.In addition, it has been suggested that alcohol consumption may be a risk factor for psoriasis onset and severity.The aim of this study was to develop evidence-based recommendations on the risk of comorbidities and its management for daily clinical use, focusing on cardiovascular risk, risk of cancer and alcohol use in psoriasis.A scientific committee identified and selected through the Delphi method clinically relevant questions about cardiovascular risk, risk of cancer and alcohol use in psoriasis. To address these questions, a systematic literature search was performed in Medline, Embase and the Cochrane Library databases. Systematic literature reviews including meta-analysis whenever possible were performed. Subsequently, an Expert board meeting involving 39 dermatologists took place to analyse the evidence and to elaborate recommendations on the selected questions. Recommendations were graded according to the Oxford level of evidence grading system. The degree of agreement of these recommendations was assessed on a 10-point scale, as well as their potential impact on daily clinical practice.A total of 3242 articles were identified through the systematic literature searches, among which 110 were included in the systematic reviews. Overall, 12 recommendations were elaborated regarding comorbidities management in psoriasis patients. A moderate increased risk of cardiovascular diseases (CVD), mainly myocardial infarction (MI) [meta-analysis of cohort studies: OR = 1.25 (95% CI 1.03-1.52) and of cross-sectional studies: OR = 1.57 (95% CI 1.08-2.27)], and coronary artery disease (CAD) [meta-analysis of cross-sectional: OR = 1.19 (95% CI 1.14-1.24), of cohort studies: OR = 1.20 (95% CI 1.13-1.27) and of case-control studies: OR = 1.84 (95% CI 1.09-3.09)] was acknowledged. This increased cardiovascular risk requires appropriate prevention measures. There was a lack of substantial evidence that conventional systemic treatment has any effect on cardiovascular risk although methotrexate might be cardioprotective. An increased risk of solid cancer potentially associated with smoking and alcohol use was identified. The role of systemic treatment on cancer risk could not be assessed thoroughly due to limited long-term follow-up data. A higher risk of non-melanoma skin cancers especially squamous cell carcinoma was shown, mainly due to previous exposure to oral 8-methoxypsoralen-ultraviolet-A (PUVA), ciclosporin and possibly methotrexate. No firm conclusion could be drawn regarding alcohol and psoriasis due to high variability in alcohol usage assessment in studies. Clinical experience suggests higher alcohol consumption among psoriasis patients compared to the general population. The mean expert participants' level of agreement on these recommendations varied from 6.8 to 9.4. These 12 recommendations are evidence based and supported by a panel of expert dermatologists. The next step is now to dis...

show abstract

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

Abstract: Psoriasis arthritis may affect up to 24% of psoriasis patients. Dermatologist should be aware of main clinical sign of PsA to promote earlier recognition and treatment of PsA.

Cited by 131 publications

References 15 publications

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Incidence of Psoriatic Arthritis in Russia: Trends at the Present Stage and Prospects

Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence‐based recommendations based on systematic review and expert opinion

Contact Info

Product

Resources

About